Maria Mora Pinzon, MD, MS, spoke to Telemundo Wisconsin about the approval of the Alzheimer’s disease treatment Leqembi (lecanemab-Irmb).
The medication was fully approved by the U.S. Food and Drug Administration (FDA) on July 6, 2023. The drug works by reducing amyloid plaques that form in the brain and is used in patients with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease. It is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
“Que Pasa Wisconsin: Información sobre ‘Leqembi’ nuevo medicamento contra el Alzheimer” was published online by Telemundo Wisconsin on July 14, 2023.